REG - Trellus Health PLC - New York Medicaid Health Plan Agreement

Trellus HealthAnnouncement

13/02/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230213:nRSM6495Pa&default-theme=true

RNS Number : 6495P  Trellus Health PLC  13 February 2023

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Trellus IBD program to be offered through New York Medicaid Health Plan

 

Demonstration project in partnership with New York State health insurer with over 1.8 million members

 

LONDON, U.K. AND NEW YORK, U.S. (13 February 2023): Trellus Health plc (AIM:
TRLS), which is commercializing a scientifically validated, personalized
resilience-driven self-management solution for chronic health conditions at
their intersection with mental health, announces that the Trellus Resilience
Training and Self-Management Solution for Inflammatory Bowel Disease (the
"Trellus IBD program") will be made available under an initial demonstration
project with a New York-based health insurance company (the "Partner") with
more than 1.8 million members.

 

The Trellus IBD program is designed to enable IBD patients to take charge of
their health needs, access behavioral and emotional support in between office
visits, and ultimately to improve outcomes. The use of digital tools for
self-care and ongoing coaching under the Trellus IBD program aligns strongly
with the Partner's goal of providing value-driven, optimized care that is
available with equal opportunity to all.

 

Under the terms of the agreement, the Trellus IBD program is now included as a
health plan benefit to certain Partner members under its Medicaid managed care
plan, to coordinate and deliver personalized behavioral, emotional and
nutritional support for the Partner's Medicaid IBD patients remotely via
digital solutions, and provide access to an expert resilience team via
telehealth. The Partner will pay for such members' enrolment and participation
in the Trellus IBD Program, with a targeted maximum enrolment of 50 patients.
The agreement will run for an initial 12-month term and can be extended by
mutual agreement, with patient enrolment to begin imminently.

 

This partnership is the culmination of the final contracting phase with a New
York Medicaid health plan which was referred to in the Company's interim
results release issued on 30 September 2022, and represents further execution
of Trellus Health's strategy to expand access to its self-management solution
through both its Direct-to-Consumer ("D2C") and
Business-to-Business-to-Consumer ("B2B2C") models. This B2B2C partnership will
provide Trellus Health with further data to strengthen the evidence base of
the ability of the Trellus IBD program to provide improvements in outcomes and
on reductions in the cost of caring for GI patients. Meeting these shared core
objectives is expected to support the wider rollout of the Trellus IBD
solution.

 

Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said: "I am
delighted to sign this B2B2C agreement with this New York State-based health
insurer to offer the Trellus IBD program to up to 50 of its members over a
12-month period. Access to the Trellus IBD program will enable the insurer to
empower its members to learn to self-manage their chronic conditions with
confidence, and improve health outcomes at a significantly lower cost. We look
forward to reviewing the data from this initial 12-month term, which will
further strengthen our evidence base as we continue discussions with other
regional and national health plans, employers, health systems, GI provider
networks and pharmaceutical companies.

 

"We look forward to working with this Health Plan to evaluate further how the
Trellus IBD program can achieve better health outcomes, and how enhanced
condition management and quality of life measures can be supported by
improvements in resilience using our approach."

 

 

For further information please contact:

 

 Trellus Health plc                                       www.trellushealth.com (http://www.trellushealth.com)
 Dr. Marla Dubinsky, CEO and Co-Founder                   Via Walbrook PR

 Dr. Daniel Mahony, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR Limited                                      Tel: 020 7933 8780 or trellus@walbrookpr.com (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen / Phillip Marriage              Mob: 07980 541 893 / 07748 651 727 / 07867 984 082

 

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (LSE: TRLS) is the first resilience based digital health
company focused on the intersection of chronic illness and mental health.
Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools and team to deliver a whole-person technology-enhanced
experience that results in relieving disease burden, building self-management
skills and promoting individual health behaviors that enable thriving in the
face of a chronic condition. Through its TrellusElevate™ connected health
platform and companion App, the company addresses both physical and behavioral
health together, in context, to improve outcomes and reduce healthcare costs
across the healthcare ecosystem.

 

The Company is initially focused on Inflammatory bowel disease ("IBD"), which
includes the chronic incurable conditions of Crohn's Disease and ulcerative
colitis, and shortly Irritable Bowel Syndrome ("IBS"), but, given the common
struggles of self-management, considers its approach to have potential utility
and demand across many chronic conditions.

 

The TrellusElevate™ platform is the Company's proprietary connected health
platform that incorporates the GRITT™ methodology and learnings on
resilience from clinical research and practice conducted at the Mount Sinai
IBD Center for more than five years. This proprietary, resilience-driven
methodology has been scientifically validated to demonstrate meaningful
improvements in patient outcomes, 71% reduction in Emergency Department
(A&E) visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for significant cost
savings for healthcare payers. Patients with IBD treated using the methodology
also experienced a 49% reduction in required opioid use and a 73% reduction in
corticosteroid use 12 months following starting the program(2).

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both with decades of combined experience in IBD and
psychogastroenterology, respectively. Trellus Health's patent-pending GRITT™
resilience assessment and personalized resilience training methodology was
developed and validated at the Mount Sinai Health System to build resilience
and wellness for improved outcomes at lower cost.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information on Trellus Health, visit:
www.trellushealth.com (http://www.trellushealth.com)

 

1) Source: https://www.cdc.gov/chronicdisease/about/costs/index.htm
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.cdc.gov_chronicdisease_about_costs_index.htm&d=DwMFaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=fSst1AtlXyuqcs3cHJXcCRilbI1Qm1WfjNYkVgQfiLE&m=IjQVBqsF0mJCc4cCch3kNewShI3X349VlYSUrh3C5-c&s=lilxcTv-hIGGEbeSix8wsDKl8TOyuP3Vw__GebvZFro&e=)
)

2) Source: https://www.sciencedirect.com/science/article/pii/S1542356521012258
(https://www.sciencedirect.com/science/article/pii/S1542356521012258) )

 

About the Trellus IBD program

Trellus Health is pioneering a scientifically validated, personalized
resilience-driven self-management solution for chronic health conditions which
addresses the intersection of chronic illness with mental health, estimated to
cost the US economy $3.7 trillion annually.(1) The Trellus approach transforms
chronic condition management and changes the lives of patients living with
debilitating, incurable conditions, initially focused on IBD, including
Crohn's Disease and ulcerative colitis, and shortly IBS, but with potential
utility and demand across many chronic conditions.

 

The Trellus IBD program is a self-management solution driven by personalized
resilience training. The program empowers and enables members to manage their
condition by teaching them to set goals, actively identify challenges and
solve problems associated with their condition, driving a change of health
behavior to deliver improved outcomes and health status at lower cost.

 

Patients with IBD face many challenges which are common across many chronic
conditions: the management of complex medication regimens, dealing with
symptoms and disability, monitoring physical indicators, maintaining proper
levels of nutrition, adjusting to the psychological and social demands
including difficult lifestyle adjustments, as well as engaging in effective
interactions with health providers.

 

Trellus's personalized resilience-driven self-management training programs are
designed specifically for people looking to overcome these challenges. The aim
is to enable patients and their physicians to achieve better quality patient
outcomes at a lower cost to health plans and employers, and the proprietary
resilience method has been proven to reduce unplanned hospitalizations by 94%
at the Mount Sinai IBD Center, New York, NY.(2)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRMZGMZMZVGFZZ